Is Your Paper Ready for eLife? The Open Science Publishing Model

ELife's IF of 6.4 puts it below Nature Communications (18.1), PLOS Biology (6.9), and several other journals publishing similar biology and medicine work. If your department or country uses impact factors for hiring and promotion decisions, this gap is real.

But context matters. eLife is a non-profit publisher that has deliberately deprioritized IF as a measure of journal quality. The assessed preprint model changes how papers accumulate citations, when a paper is available as a preprint with public reviews before its "final" form, citation patterns differ from a paper that only becomes visible upon formal acceptance. None of this changes the political reality of academic career progression. If your tenure committee counts IFs, factor that in.

But if the quality and visibility of your specific paper matter more than the journal's aggregate metric, eLife becomes a much more interesting option.

In a traditional journal, your paper goes through peer review behind closed doors. eLife flips this. Every paper eLife sends for peer review is published as a Reviewed Preprint (the "assessed preprint" model this guide describes): the preprint together with an eLife Assessment, the Public Reviews, and your response if you provide one, available for anyone to read alongside expert evaluations of its strengths and weaknesses. You then decide whether to revise and request a Version of Record or let the Reviewed Preprint stand on its own.

This model changes the incentives in ways that matter. Reviewers know their assessments will be public, which tends to make reviews more constructive and less adversarial. Authors get credit for their work even if they don't clear every revision hurdle. And readers get to see what experts actually thought about the paper, rather than assuming that "published" means "flawless."

The practical implication: your work will be evaluated in public. If the reviewers identify a fatal flaw, that assessment will be visible. If they praise your methodology but flag a limitation, both will be on the record. For researchers doing careful, reproducible work, this transparency is overwhelmingly a feature.

Most journals charge APCs after acceptance. eLife charges $3,750 when the editors decide to send your paper for external review. If the reviewers find problems you can't address, or you decide not to revise, the fee does not depend on that outcome.

Charging at the review stage rather than on acceptance means payment is not tied to an accept decision, and eLife publishes every article it reviews.

From your perspective: be highly confident before your paper reaches review. The good news is that editorial screening (median 8 days when a paper is not selected, no charge) filters out roughly 65-73% of submissions. If your paper enters review, the editors have already made a meaningful judgment. But "worth evaluating" and "will be accepted" aren't the same thing.

For APC comparison: Nature Communications charges ~$7,350, PNAS ~$5,450, Science Advances ~$5,450. At $3,750, eLife is cheaper in absolute terms, but the fee-at-review structure means you're paying in a higher-risk scenario.

A few patterns emerge from this comparison. eLife has the lowest IF and an APC below Nature Communications and EMBO Journal. It's the only journal that charges before acceptance and the only one with a fully public assessed preprint model. Nature Communications has a much higher IF and acceptance rate but costs twice as much and is run by a for-profit publisher (Springer Nature). PLOS Biology and EMBO Journal both sit between eLife and Nature Communications on most metrics but don't offer the assessed preprint model or public reviewer reports.

The question you need to ask isn't "which journal has the highest IF?" It's "which journal aligns with how I think science should be communicated, given the practical constraints I'm working under?"

Data quality over novelty claims. Papers with exceptional datasets, rigorous controls, and reproducible methods tend to do better than papers with bold claims supported by thinner evidence. eLife says it will not decline a paper only because similar work has been published or posted, but it generally does not review papers that appear to report incremental results, or ones that are obviously flawed.

Reproducibility signals. eLife pays close attention to whether your methods section is detailed enough for replication. Reagents with catalog numbers, available analysis scripts, deposited raw data, these are part of the editorial evaluation, not afterthoughts.

Transparent reporting. Pre-registration, power analyses, and other transparency practices are valued. You don't need all of them, but having any strengthens your submission.

Biological or medical significance. Your work needs to address a question that matters to the biology or medicine community. Technical advances are welcome (eLife publishes Tools and Resources articles), but they need to show how they will enable biological advances.

With roughly 65-73% of submissions declined before review, the screening (median 8 days when a paper is not selected) is the first real hurdle. Editors evaluate scope, significance, and obvious methodological red flags.

Your title and abstract carry disproportionate weight. Lead with what you found, not with what you studied. "CRISPR-Cas9 editing of gene X restores function Y in Z disease model" beats "Investigation of gene X in disease Z."

Your cover letter should explain why this paper fits eLife specifically. Mention the data quality emphasis. Show that you understand what makes eLife different from the ten other journals you could have submitted to.

If your paper passes screening, eLife reports a median of 96 days from submission to a published Reviewed Preprint (2025). Part of that speed comes from the editorial model (eLife's editors are all active researchers) and from the preprint-first design.

Reviews tend to be detailed and constructive, public accountability changes the tone. You're less likely to get the anonymous "reject because I don't like this lab's approach" review. You're more likely to get specific, actionable feedback on methodology, analysis, and interpretation. After review, eLife issues an eLife Assessment, Public Reviews, and recommendations for the authors. The Assessment and Public Reviews are published with the Reviewed Preprint; the recommendations are published with revised versions and the Version of Record.

A eLife manuscript fit check at this stage can identify scope mismatches and common structural issues before you finalize your submission.

ELife's submission system is at elife-rp.msubmit.net, not Editorial Manager or ScholarOne.

Front-load your methods. Include enough detail that an independent lab could replicate your key experiments without contacting you.

Deposit your data early. Get sequencing data into GEO/SRA, proteomics into PRIDE, structural data into PDB before you submit. Include accession numbers in your manuscript.

Prepare for public scrutiny. Your figures, statistical analyses, and conclusions will all be evaluated in reviews that become public. Double-check everything. Run your statistics again. Make sure your figure labels are accurate. Small errors that might slide past reviewers at other journals become permanent public records at eLife.

Write for clarity, not for impressiveness. eLife's reviewer pool tends to appreciate clear, direct writing over jargon-heavy prose. State what you did, what you found, and what it means. Don't oversell.

Running your manuscript through a eLife scope and framing check can help identify whether your abstract effectively communicates your data's strength, whether your methods section meets eLife's reproducibility expectations, and whether your conclusions match what your data actually supports.

This kind of check is especially valuable when you're submitting to a journal with a non-traditional model. What works in a cover letter for Nature won't work for eLife. The framing that impresses Cell editors (bold mechanistic claims) might actually hurt you at eLife if the data doesn't fully support those claims. Getting feedback calibrated to eLife's specific priorities can prevent a $3,750 mistake.

For manuscripts targeting eLife, five patterns generate the most consistent desk rejections worth knowing before submission.

Claims not adequately supported by the evidence (~35%). The life sciences paper that makes important claims without sufficient evidence to support them at eLife's impact threshold.

The eLife author guide states that every article eLife reviews is published as a Reviewed Preprint, and the Public Reviews indicate whether claims are adequately supported; editors consistently flag papers where the advance relies on underpowered experiments or single biological replicates, and those public concerns limit post-publication impact even when the paper is published.

In our experience, many of the papers we review for eLife have this problem in at least one key claim.

Computational models without experimental validation (~25%). The systems or computational biology paper without experimental validation of the key model predictions. Editors consistently expect computational biology papers to include experimental tests of the top predictions from the model, not only the computational framework itself. In our experience, roughly 25% of computational submissions we review are missing this validation component.

Single-manipulation neuroscience conclusions (~20%). The neuroscience paper with behavioral conclusions derived from a single genetic manipulation without pharmacological or rescue validation. Editors consistently raise challenges about specificity of the interpretation when convergent evidence from multiple approaches is absent. In our experience, roughly 20% of neuroscience papers we see at eLife face this objection in public review.

Missing structural data deposition (~15%). The structural biology paper that has not deposited coordinates and structure factors in the PDB or EMDB before publication. Editors consistently treat deposition as a condition of publication, not a post-acceptance step; submissions where deposition is not completed or clearly planned face desk rejection. In our experience, roughly 15% of structural biology submissions we see have not completed or confirmed this step.

Overexpression artifacts unaddressed (~10%). The cell biology paper that uses only overexpression systems without demonstrating that endogenous protein levels produce the same phenotype. Editors consistently flag artifacts from non-physiological expression levels as a standard concern for papers making claims about endogenous protein function. In our experience, roughly 10% of cell biology papers we review for eLife have this gap.

Before submitting to eLife, an eLife submission readiness check identifies whether your evidence base, experimental validation, and data deposition meet eLife's editorial bar before you commit to the submission.

Ready to submit if:

• You can pass every item on this checklist without qualifying language

• An experienced colleague in your field has read the manuscript and agrees it's competitive

• The data package is complete - no pending experiments or analyses

• You have identified why this journal specifically (not just prestige) is the right venue

Not ready yet if:

• You skipped items on this checklist because you "plan to add them later"

• The methods section still has draft or incomplete protocol text

• Key figures are drafts rather than publication-quality

• You cannot articulate what distinguishes this paper from recent publications in this journal

For a manuscript-specific signal before you submit, run a free readiness scan.

Ready and well-matched are two different questions. See where eLife lands among the venues that fit my abstract.

• Manusights local fit and process context from eLife acceptance rate, eLife submission guide, and eLife cover letter.